Targeting VDAC1 is likely to be effective for conditions associated with altered cell metabolism and/or apoptosis and by VDAC1 overexpression [29,51,99,146,147], which we suggest may be a common mechanism in the pathology of CVDs, AD, and T2D. Here, VDAC1 is linked to type 2 diabetes mellitus.